Target Name: EIF6
NCBI ID: G3692
Review Report on EIF6 Target / Biomarker Content of Review Report on EIF6 Target / Biomarker
EIF6
Other Name(s): OTTHUMP00000061360 | b(2)gcn | EIF3A | eIF-6 | Eukaryotic translation initiation factor 6, transcript variant 2 | EIF6 variant 1 | ITGB4BP | p27 beta-4 integrin-binding protein | Eukaryotic translation initiation factor 6 | eukaryotic translation initiation factor 6 | Eukaryotic translation initiation factor 6, transcript variant 1 | EIF-6 | Eukaryotic translation initiation factor 6 (isoform a) | B(2)GCN homolog | OTTHUMP00000030734 | Eukaryotic translation initiation factor 3A | gcn | eukaryotic translation initiation factor 3A | B4 integrin interactor | Integrin beta 4 binding protein | p27(BBP) | OTTHUMP00000061361 | EIF6 variant 2 | P27 beta-4 integrin-binding protein | IF6_HUMAN | CAB | p27BBP

EIF6 as A Potential Drug Target for Neurodegenerative Diseases

EIF6 (endoplasmic reticulum-resident factor 6) is a protein that is expressed in various tissues throughout the body. It is a key regulator of protein synthesis and has been identified as a potential drug target in the field of neurodegenerative diseases.

EIF6 is a member of the Endoplasmic Reticulum (ER) family, which includes a variety of proteins that play important roles in regulating protein synthesis and degradation. The ER is a specialized organ that functions as a quality control center for the cell, where proteins are translated from mRNA into functional proteins.

One of the key functions of EIF6 is its role as a protein stability regulator. EIF6 helps to maintain the stability of a variety of proteins in the ER, by interacting with multiple cellular signaling pathways. This is important for ensuring that these proteins are properly retained in the ER and not released into the cytoplasm, where they could cause harmful effects on other cellular processes.

Another important function of EIF6 is its role as a protein synthesis regulator. EIF6 helps to regulate the rate at which proteins are synthesized in the ER, by interacting with the protein synthesis machinery. This is important for ensuring that the cell has enough proteins to meet its protein needs, and for preventing the buildup of misfolded or damaged proteins that could cause neurodegenerative diseases.

EIF6 has also been shown to play a role in the regulation of cellular signaling pathways. In particular, EIF6 has been shown to interact with the protein p53, which is a well-known tumor suppressor protein. This interaction allows EIF6 to regulate the activity of p53, and to play a role in the regulation of cellular processes that are important for the development and progression of neurodegenerative diseases.

In addition to its role as a protein stability and synthesis regulator, EIF6 has also been shown to play a role in the regulation of cellular interactions with the cell membrane. This is important for ensuring the integrity of the cell membrane, and for preventing the unauthorized entry of toxins or other harmful substances into the cell.

Given its multiple functions in regulating protein synthesis and cellular signaling pathways, it is not surprising that EIF6 has been identified as a potential drug target in the field of neurodegenerative diseases. Studies have shown that EIF6 can be targeted with small molecules, and that this can lead to the inhibition of its functions as a protein stability and synthesis regulator. This suggests that EIF6 may be a useful target for the development of new treatments for a variety of neurodegenerative diseases.

In conclusion, EIF6 is a protein that has been identified as a potential drug target in the field of neurodegenerative diseases. Its multiple functions as a protein stability and synthesis regulator, as well as its role in the regulation of cellular signaling pathways and interactions with the cell membrane, make it an attractive target for the development of new treatments for a variety of neurodegenerative diseases. Further research is needed to fully understand the functions of EIF6, and to determine the most effective and safe methods for its targeting.

Protein Name: Eukaryotic Translation Initiation Factor 6

Functions: Binds to the 60S ribosomal subunit and prevents its association with the 40S ribosomal subunit to form the 80S initiation complex in the cytoplasm (PubMed:10085284, PubMed:14654845, PubMed:21536732, PubMed:32669547). Behaves as a stimulatory translation initiation factor downstream insulin/growth factors. Is also involved in ribosome biogenesis. Associates with pre-60S subunits in the nucleus and is involved in its nuclear export. Cytoplasmic release of TIF6 from 60S subunits and nuclear relocalization is promoted by a RACK1 (RACK1)-dependent protein kinase C activity (PubMed:10085284, PubMed:14654845, PubMed:21536732). In tissues responsive to insulin, controls fatty acid synthesis and glycolysis by exerting translational control of adipogenic transcription factors such as CEBPB, CEBPD and ATF4 that have G/C rich or uORF in their 5'UTR. Required for ROS-dependent megakaryocyte maturation and platelets formation, controls the expression of mitochondrial respiratory chain genes involved in reactive oxygen species (ROS) synthesis (By similarity). Involved in miRNA-mediated gene silencing by the RNA-induced silencing complex (RISC). Required for both miRNA-mediated translational repression and miRNA-mediated cleavage of complementary mRNAs by RISC (PubMed:17507929). Modulates cell cycle progression and global translation of pre-B cells, its activation seems to be rate-limiting in tumorigenesis and tumor growth (By similarity)

The "EIF6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EIF6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

EIPR1 | ELAC1 | ELAC2 | ELANE | ELAPOR1 | ELAPOR2 | Elastase | ELAVL1 | ELAVL2 | ELAVL3 | ELAVL4 | ELDR | ELF1 | ELF2 | ELF2P4 | ELF3 | ELF3-AS1 | ELF4 | ELF5 | ELFN1 | ELFN1-AS1 | ELFN2 | ELK1 | ELK2AP | ELK3 | ELK4 | ELL | ELL2 | ELL2P1 | ELL3 | ELMO1 | ELMO2 | ELMO3 | ELMOD1 | ELMOD2 | ELMOD3 | ELN | ELOA | ELOA-AS1 | ELOA2 | ELOA3BP | ELOA3DP | ELOA3P | ELOB | ELOC | ELOF1 | Elongation Factor 1 Complex | Elongation of very long chain fatty acids protein | Elongin (SIII) complex | ELOVL1 | ELOVL2 | ELOVL2-AS1 | ELOVL3 | ELOVL4 | ELOVL5 | ELOVL6 | ELOVL7 | ELP1 | ELP2 | ELP3 | ELP4 | ELP5 | ELP6 | ELSPBP1 | EMB | EMBP1 | EMC1 | EMC1-AS1 | EMC10 | EMC2 | EMC3 | EMC3-AS1 | EMC4 | EMC6 | EMC7 | EMC8 | EMC9 | EMCN | EMD | EME1 | EME2 | EMG1 | EMID1 | EMILIN1 | EMILIN2 | EML1 | EML2 | EML2-AS1 | EML3 | EML4 | EML4-AS1 | EML5 | EML6 | EMP1 | EMP2 | EMP2P1 | EMP3 | EMSLR | EMSY | EMX1